Neurol. praxi. 2025;26(3):192-196 | DOI: 10.36290/neu.2025.007

Evaluating the efficacy of treatment for multiple sclerosis in the practice; development of the NEDA concept

prof. MUDr. Eva Kubala Havrdová, DrSc.
Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN Praha

With the advent of highly effective treatment for multiple sclerosis, it is currently possible to consider even long-term remission. The NEDA (no evidence of disease activity) concept was introduced following the evaluation of a clinical trial with natalizumab. Since then, it has been used to evaluate the effect in studies with novel drugs, allowing their comparison. It involves the assessment of relapse rates, progression, and MRI findings. It would certainly be possible to add many more items; however, even in this simple form, it is very difficult to achieve in the long term in the majority of patients.

Keywords: multiple sclerosis, NEDA concept, MRI, neurofilament light chains.

Received: January 18, 2025; Revised: January 18, 2025; Accepted: January 18, 2025; Prepublished online: January 18, 2025; Published: July 4, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kubala Havrdová E. Evaluating the efficacy of treatment for multiple sclerosis in the practice; development of the NEDA concept. Neurol. praxi. 2025;26(3):192-196. doi: 10.36290/neu.2025.007.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 4.7.2026

    References

    1. . Bittner S, Oh J, Havrdová EK, et al. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain. 2021 Nov 29;144(10):2954-2963. doi: 10.1093/brain/awab241. PMID: 34180982; PMCID: PMC8634125. Go to original source... Go to PubMed...
    2. . Giovannoni G, Cook S, Rammohan K, et al.; CLARITY study group. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011 Apr;10(4):329-37. doi: 10.1016/S1474-4422(11)70023-0. PMID: 21397565. Go to original source... Go to PubMed...
    3. . Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the 'real MS'. Ther Adv Neurol Disord. 2022 Jan 25;15:17562864211066751. doi: 10.1177/17562864211066751. PMID: 35096143; PMCID: PMC8793117. Go to original source... Go to PubMed...
    4. . Giovannoni G, Tomic D, Bright JR, Havrdová E. "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017 Aug;23(9):1179-1187. doi: 10.1177/1352458517703193. Epub 2017 Apr 6. PMID: 28381105; PMCID: PMC5536258. Go to original source... Go to PubMed...
    5. . Havrdová E, a kol. Roztroušená skleróza, MF 2013, ISBN 978-80-204-3154-7.
    6. . Havrdová E, Arnold DL, Bar-Or A, et al. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. PMID: 29568544; PMCID: PMC5858626. Go to original source... Go to PubMed...
    7. . Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar;8(3):254-60. doi: 10.1016/S1474-4422(09)70021-3. Epub 2009 Feb 7. PMID: 19201654. Go to original source... Go to PubMed...
    8. . Havrdova E, Giovannoni G, Stefoski D, et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler. 2014 Apr;20(4):464-70. doi: 10.1177/1352458513502113. Epub 2013 Sep 10. PMID: 24022270. Go to original source... Go to PubMed...
    9. . Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2016 Sep;22(10):1297-305. doi: 10.1177/1352458515616701. Epub 2015 Nov 19. PMID: 26585439; PMCID: PMC5015759. Go to original source... Go to PubMed...
    10. . Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020 Sep 1;77(9):1132-1140. doi: 10.1001/jamaneurol.2020.1568. PMID: 32511687; PMCID: PMC7281382. Go to original source... Go to PubMed...
    11. . Lebrun-Frénay C, Siva A, Sormani MP, et al. TERIS Study Group. Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial. JAMA Neurol. 2023 Oct 1;80(10):1080-1088. doi: 10.1001/jamaneurol.2023.2815. PMID: 37603328; PMCID: PMC10442780. Go to original source... Go to PubMed...
    12. . Okuda DT, Kantarci O, Lebrun-Frénay C, et al. Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. Ann Neurol. 2023 Mar;93(3):604-614. doi: 10.1002/ana.26555. Epub 2022 Dec 10. PMID: 36401339. Go to original source... Go to PubMed...
    13. . Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011 Aug;17(8):970-9. doi: 10.1177/1352458511399611. Epub 2011 Mar 18. PMID: 21421809. Go to original source... Go to PubMed...
    14. . Polman CH, O'Connor PW, Havrdova E, et al.; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397. PMID: 16510744. Go to original source... Go to PubMed...
    15. . Rotstein DL, Healy BC, Malik MT, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015 Feb;72(2):152-8. doi: 10.1001/jamaneurol.2014.3537. Go to original source... Go to PubMed...
    16. . Uher T, Havrdova EK, Benkert P, et al. Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Mult Scler. 2021 Nov;27(13):2001-2013. doi: 10.1177/13524585211047977. Epub 2021 Oct 6. PMID: 34612753. Go to original source... Go to PubMed...
    17. . Uher T, Havrdova E, Sobisek L, et al. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up? Mult Scler. 2017 Feb;23(2):242-252. doi: 10.1177/1352458516650525. Epub 2016 Jul 11. PMID: 27230790. Go to original source... Go to PubMed...
    18. . University of California, San Francisco MS-EPIC Team, Cree BAC, Hollenbach JA, Bove R, e tal. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019 May;85(5):653-666. doi: 10.1002/ana.25463. Epub 2019 Mar 30. PMID: 30851128; PMCID: PMC6518998. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.